-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
VALBIOTIS SA: Valbiotis® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist in natural solutions and prevention
28 Nov 2024 17:40 CET
Issuer
VALBIOTIS S.A.
|
VALBIOTIS SA
Valbiotis® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist in natural solutions and prevention
La Rochelle, Thursday, November 28 (5:40 P.M. CEST) – Valbiotis® (FR0013254851 – ALVAL, PEA-PME eligible), Valbiotis®, a French scientific research laboratory specialized in the marketing of dietary supplements scientifically proven to prevent metabolic and cardiovascular diseases and maintain optimal daily health, has signed a partnership with Asetys, a complementary health insurance provider specializing in natural therapies. The two companies will be working together to democratize access to natural therapies and maintain better health.
Growth potential The dietary supplements market is growing rapidly and attracting increasing attention. 61%* of French people consume dietary supplements several times a year, including to prevent certain illnesses. 81%* seek natural products to maintain their health. This new collaboration between Valbiotis® and Asetys meets a strong and growing demand for accessible healthcare products tailored to individual needs. “Our partnership with Asetys will help us raise awareness of the importance of prevention and holistic care among a wide audience of both patients and therapists. We are uniting our expertise to bring natural health products within reach of everyone,” said Sébastien Peltier, PhD, CEO and co-founder of Valbiotis®.
Educational workshops and natural solutions for partner therapists and policyholders As of January 7, 2025, Asetys members will receive reimbursements for products developed by the Valbiotis® laboratory, to facilitate access to wellness and prevention solutions. As part of this partnership, Valbiotis® will also be organizing themed educational workshops to support Asetys’ partner wellness practitioners and therapists as well as its members. These workshops will focus on key health and wellness issues with the aim of raising awareness of the importance of prevention and providing information to encourage a more proactive and informed approach to health. These arenas for discussion are also unique opportunities to collaborate with healthcare professionals and share knowledge and know-how.
*2024 barometer of dietary supplement consumption in France – sample of 1,049 French people aged 18 and over, representative of the population as a whole – February 2024
About Valbiotis® Valbiotis® is a French scientific research laboratory specializing in the development and marketing of dietary supplements to prevent and combat the metabolic disorders that cause cardiovascular disease. Valbiotis® has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of natural dietary supplements designed to reduce the impact of metabolic disorders and minimize cardiovascular risk factors. This approach relies on a multi-target strategy made possible with the use of plant-based resources. In France, Valbiotis® is responsible for marketing its own products. Internationally, its products are the subject of licensing agreements. Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. Valbiotis® is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis® has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis® is a PEA-SME eligible company. For more information about Valbiotis®, please visit: www.valbiotis.com
About Asetys Asetys has been operating as a natural prevention ecosystem since 2015, expanding an innovative complementary health insurance service integrating a professional network of partner wellness practitioners, therapists and laboratories. Asetys chooses its partner laboratories for the excellent quality of their products. For more information, please visit: https://asetys.fr
Contacts Corporate Communication / Valbiotis® Caroline Lamberti +33 5 46 28 62 58 caroline.lamberti@valbiotis.com
Financial Communication / Seitosei-Actifin Marianne Py +33 1 80 48 25 31 marianne.py@seitosei-actifin.com
Press Relations / Seitosei-Actifin + 33 1 56 88 11 14 michael.scholze@seitosei-actifin.com
Regulatory filing PDF file File: CP Asetys Valbiotis EN_revu Monet_vf |
| Language: | English |
| Company: | VALBIOTIS SA |
| 12F, Rue Paul Vatine | |
| 17180 Périgny | |
| France | |
| Phone: | 0546286258 |
| E-mail: | contact@valbiotis.com |
| Internet: | www.valbiotis.com |
| ISIN: | FR0013254851 |
| Euronext Ticker: | ALVAL |
| AMF Category: | Inside information / Other releases |
| EQS News ID: | 2040653 |
| End of Announcement | EQS News Service |
2040653 28-Nov-2024 CET/CEST
WDUBGTJEHSJUTAMHKXCHMJJB_CP_Asetys_Valbiotis_EN_revu_Monet_vf.pdf
Source
VALBIOTIS SA
Provider
EQS Group
Company Name
VALBIOTIS
ISIN
FR0013254851
Symbol
ALVAL
Market
Euronext Growth